Starling, Naureen
Cunningham, David http://orcid.org/0000-0001-5158-1069
Article History
Received: 15 September 2022
Revised: 21 December 2022
Accepted: 9 January 2023
First Online: 16 February 2023
Competing interests
: Within the last 5 years, COI for both authors is detailed: NS and DC are supported by the NIHR Biomedical Research Centre at The Royal Marsden and Institute for Cancer Research. NS is supported by the following grants: NIHR NIHR128529 and SBRI SBRIC01P3008. DC is supported by NIHR128529. NS: Honoraria: Merck Serono, Novartis, MSD Oncology, Eli Lilly, Pierre Fabre, Amgen, GSK, Servier, Pierre Fabre. Advisory role; Pfizer, Servier, AstraZeneca, MSD Oncology Novartis, Bayer, GSK, Guardant Health, Gilead, Seagen; Research support: Pfizer, AstraZeneca, Guardant Health Travel/accommodation support: Roche, BMS, MSD DC: Research funding: MedImmune/AZ, Clovis, Eli Lilly, 4SC, Bayer, Celgene, Leap, Advisory: OVIBIO.